Can a blood product fix smallpox vaccine side effects?

NCT ID NCT01374984

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether VIGIV, a blood product with antibodies, helps people who have serious reactions to the smallpox vaccine. It will track 100 patients to see if their skin lesions improve and if their antibody levels change. The goal is to confirm that VIGIV works as a treatment for these rare but severe complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vaccinia Immune Globulin Intravenous (Human) (VIGIV)

What this could lead to

If successful, this could confirm that VIGIV effectively treats serious complications from smallpox vaccination, providing a reliable treatment option.

What could go wrong

This is an observational post-marketing study, not a controlled trial, so results may be less definitive. The small sample size (100) and lack of a comparison group limit how strongly we can conclude effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMPLICATION OF SMALLPOX VACCINATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

smallpox vaccinia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.